The use of avoparcin as a growth promoter and the occurrence of vancomycin-resistant Enterococcus species in Norwegian poultry and swine production.
This study documents a strong and statistically significant association between the use of the glycopeptide avoparcin as a growth promoter in Norwegian poultry production and the occurrence of vancomycin-resistant Enterococcus species (VRE). Avoparcin was approved as a feed additive for broilers and turkeys in Norway in 1986 and was banned from June 1, 1995. In a survey conducted in Norway between June, 1995 and March, 1997, VRE were isolated from fecal samples from 106 out of 109 poultry houses previously exposed to avoparcin (97%) and from six out of 33 poultry houses never exposed to avoparcin (18%) (RR = 5.35). Samples from previously exposed poultry houses were collected in three time periods. The proportion of positive samples remained high (96-98%), in all three time periods indicating a persistence of vancomycin resistance among enterococci for more than a year and a half after the withdrawal of avoparcin. VRE were also isolated from six out of 10 poultry farmers living on farms previously exposed to avoparcin, and from none of 16 farmers living on farms never exposed to avoparcin. Moreover, VRE were isolated from 68 out of the 225 broiler carcasses investigated (30%). The resistance to vancomycin was a high-level type (MIC > or = 256 microg/ml) mediated by the vanA gene. For comparison, VRE could only be isolated from two out of 147 fecal samples from Norwegian flocks of swine (1%). Because avoparcin never has been used in Norwegian swine production, this observation strengthens the association between the use of avoparcin in animal husbandry and the occurrence of VRE.
Kruse
H
H
Department of Food and Feed Hygiene, National Veterinary Institute, The Norwegian School of Veterinary Science, Oslo, Norway.
Johansen
B K
BK
Rørvik
L M
LM
Schaller
G
G
D000822:Animal Husbandry; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002645:Chickens / Q000254:growth & development*; D004352:Drug Resistance, Microbial; D016983:Enterococcus / Q000187:drug effects / Q000302:isolation & purification*; D005243:Feces / Q000382:microbiology; D006020:Glycopeptides; D006133:Growth Substances / Q000494:pharmacology*; D013552:Swine / Q000254:growth & development*; D014640:Vancomycin / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D006133:Growth Substances; D014640:Vancomycin; C016249:avoparcin